Genmab A/S
Toldbodgade 33
Copenhagen
K-1253
Tel: 45-7020-2728
Fax: 45-7020-2729
Website: http://www.genmab.com/
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.YEAR FOUNDED:
February 1999
LEADERSHIP:
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW GENMAB: Tweets by Genmab
402 articles with Genmab A/S
-
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
5/12/2022
Genmab A/S announced that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.
-
Genmab Announces Financial Results for the First Quarter of 2022
5/11/2022
Genmab Announces Financial Results for the First Quarter of 2022.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
4/19/2022
Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD1,856million in the first quarter of 2022.
-
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
4/13/2022
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody.
-
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
4/7/2022
Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.
-
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
3/8/2022
Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL).
-
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
2/24/2022
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck.
-
Notice to Convene the Annual General Meeting of Genmab A/S
2/24/2022
COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, KalvebodBrygge 5, DK-1560 Copenhagen V, Denmark.
-
Genmab Publishes 2021 Annual Report
2/16/2022
Genmab A/S announced the publication of its Annual Report for 2021.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
1/25/2022
Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.
-
Genmab and Synaffix Enter into License Agreement for ADC Technology
1/4/2022
Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.
-
The approval was based on Phase II data from the PLEIADES study that showed patients treated with the combination therapy generated an overall response rate of 84.8%.
-
Genmab Announces Financial Results for the First Nine Months of 2021
11/10/2021
Genmab Announces Financial Results for the First Nine Months of 2021
-
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
-
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
11/4/2021
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
-
Genmab Improves its 2021 Financial Guidance
11/4/2021
Genmab A/S announced that it is improving its 2021 financial guidance published on August 11, 2021.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
10/19/2021
Copenhagen, Denmark; October 19, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,580million in the third quarter of 2021.
-
The U.S. FDA is kicking off the month of October with a number of PDUFA dates and an advisory committee meeting. Read on for more details.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
9/20/2021
Seagen Inc. and Genmab A/S announced that the U.S. Food and Drug Administration has granted accelerated approval to TIVDAK™, the first and only approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.